Cargando…
X‐linked inhibitor of apoptosis inhibition sensitizes acute myeloid leukemia cell response to TRAIL and chemotherapy through potentiated induction of proapoptotic machinery
Acute myeloid leukemia (AML) is an aggressive disease with an increasing incidence and relatively low 5‐year survival rate. Unfortunately, the underlying mechanism of leukemogenesis is poorly known, and there has been little progress in the treatment for AML. Studies have shown that X‐linked inhibit...
Autores principales: | Zhou, Jianbiao, Lu, Xiao, Tan, Tuan Zea, Chng, Wee‐Joo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748481/ https://www.ncbi.nlm.nih.gov/pubmed/29063676 http://dx.doi.org/10.1002/1878-0261.12146 |
Ejemplares similares
-
BET Bromodomain inhibition promotes De-repression of TXNIP and activation of ASK1-MAPK pathway in acute myeloid leukemia
por: Zhou, Yafeng, et al.
Publicado: (2018) -
Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies
por: Zhou, Jianbiao, et al.
Publicado: (2018) -
Aberrant nuclear factor-kappa B activity in acute myeloid Leukemia: from molecular pathogenesis to therapeutic target
por: Zhou, Jianbiao, et al.
Publicado: (2015) -
Inhibition of LIN28B impairs leukemia cell growth and metabolism in acute myeloid leukemia
por: Zhou, Jianbiao, et al.
Publicado: (2017) -
ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia
por: Zhou, Jianbiao, et al.
Publicado: (2019)